Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | GCK | P35557 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10576592 | 0.91 | MEN1 (0.38) | MEN1KMT2AGRM5KDM4CGCK | |
| SCHEMBL11813613 | 0.85 | MEN1 (0.35) | MEN1KMT2AGRM5KDM4CGCK | |
| SCHEMBL2989785 | 0.85 | MEN1 (0.35) | MEN1KMT2AGRM5KDM4CGCK | |
| SCHEMBL10679266 | 0.84 | MEN1 (0.35) | MEN1KMT2AGRM5KDM4CL3MBTL1 | |
| SCHEMBL5369982 | 0.82 | MEN1 (0.34) | MEN1KMT2AGRM5KDM4CL3MBTL1 | |
| SCHEMBL21437122 | 0.82 | MEN1 (0.37) | MEN1KMT2AGRM5KDM4CGCK | |
| SCHEMBL1921106 | 0.82 | MEN1 (0.34) | MEN1KMT2AGRM5KDM4CL3MBTL1 | |
| SCHEMBL1227411 | 0.82 | MEN1 (0.34) | MEN1KMT2AGRM5KDM4CGCK | |
| SCHEMBL2988696 | 0.82 | MEN1 (0.37) | MEN1KMT2AGRM5KDM4CGCK | |
| SCHEMBL28974733 | 0.81 | MEN1 (0.33) | MEN1KMT2AGRM5KDM4CL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3940425-A | Process for the production of polyunsaturated compounds | BAYER AKTIENGESELLSCHAFT (DT) | 1976-02-24 | — | — | US | claimed |
| US-9126926-B2 | Oligomer-anticholinergic agent conjugates | NEKTAR THERAPEUTICS (US) | 2015-09-08 | — | — | US | disclosed |
| US-9126926-B2 | Oligomer-anticholinergic agent conjugates | NEKTAR THERAPEUTICS (US) | 2015-09-08 | — | — | US | disclosed |
| US-20130150441-A1 | Oligomer-Anticholinergic Agent Conjugates | NEKTAR THERAPEUTICS (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150441-A1 | Oligomer-Anticholinergic Agent Conjugates | NEKTAR THERAPEUTICS (US) | 2013-06-13 | — | — | US | disclosed |
| EP-2134370-B1 | Oligomer-anticholinergic agent conjugates | NEKTAR THERAPEUTICS (US) | 2013-04-17 | — | — | EP | disclosed |
| EP-2134370-B1 | Oligomer-anticholinergic agent conjugates | NEKTAR THERAPEUTICS (US) | 2013-04-17 | — | — | EP | disclosed |
| US-8389759-B2 | Oligomer-anticholinergic agent conjugates | NEKTAR THERAPEUTICS (US) | 2013-03-05 | — | — | US | disclosed |
| US-20100184989-A1 | De Novo Synthesis of Conjugates | NEKTAR THERAPEUTICS (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100168232-A1 | Oligomer-Anticholinergic Agent Conjugates | NEKTAR THERAPEUTICS (US) | 2010-07-01 | — | — | US | disclosed |
| EP-2134370-A1 | OLIGOMER-ANTICHOLINERGIC AGENT CONJUGATES | Nektar Therapeutics (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-2125027-A2 | DE NOVO SYNTHESIS OF CONJUGATES | Nektar Therapeutics (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008112286-A9 | DE NOVO SYNTHESIS OF CONJUGATES | NEKTAR THERAPEUTICS AL CORP (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008112286-A2 | DE NOVO SYNTHESIS OF CONJUGATES | NEKTAR THERAPEUTICS (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112261-A1 | OLIGOMER-ANTICHOLINERGIC AGENT CONJUGATES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2008-09-18 | — | — | WO | disclosed |
| US-3940425-A | Process for the production of polyunsaturated compounds | BAYER AKTIENGESELLSCHAFT (DT) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168232-A1 | Oligomer-Anticholinergic Agent Conjugates | CHRM3, CHRM4, CHRM5 | MEN1 3299/4885KMT2A 2254/4885GRM5 592/4885 |
| US-20100184989-A1 | De Novo Synthesis of Conjugates | ABCG2, UGT1A8, SLC7A5 | MEN1 2662/4885KMT2A 2362/4885GRM5 973/4885 |
| US-20130150441-A1 | Oligomer-Anticholinergic Agent Conjugates | CHRM3, CHRM4, CHRM5 | MEN1 3321/4885KMT2A 2399/4885GRM5 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.